Literature DB >> 20139388

Molecular basis of juvenile myelomonocytic leukemia.

Andrica C H de Vries, C Michael Zwaan, Marry M van den Heuvel-Eibrink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20139388      PMCID： PMC2817017          DOI： 10.3324/haematol.2009.016865

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  30 in total

Review 1.  The Cbl interactome and its functions.

Authors:  Mirko H H Schmidt; Ivan Dikic
Journal:  Nat Rev Mol Cell Biol       Date:  2005-12       Impact factor: 94.444

2.  Syndromes run together in the RAS pathway.

Authors: 
Journal:  Nat Genet       Date:  2006-03       Impact factor: 38.330

3.  Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia.

Authors:  C P Kratz; C M Niemeyer; C Thomas; S Bauhuber; V Matejas; E Bergsträsser; C Flotho; N J Flores; O Haas; H Hasle; M M van den Heuvel-Eibrink; R S Kucherlapati; P Lang; A E Roberts; J Starý; B Strahm; K D Swanson; M Trebo; M Zecca; B Neel; F Locatelli; M L Loh; M Zenker
Journal:  Leukemia       Date:  2007-02-22       Impact factor: 11.528

4.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

5.  Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.

Authors:  C Flotho; D Steinemann; C G Mullighan; G Neale; K Mayer; C P Kratz; B Schlegelberger; J R Downing; C M Niemeyer
Journal:  Oncogene       Date:  2007-03-12       Impact factor: 9.867

Review 6.  RAS pathway mutations in juvenile myelomonocytic leukemia.

Authors:  Peter D Emanuel
Journal:  Acta Haematol       Date:  2008-06-20       Impact factor: 2.195

7.  Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; Ronald W Stam; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

8.  Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; Ronald W Stam; Pauline Schneider; Charlotte M Niemeyer; Elisabeth R van Wering; Oskar A Haas; Christian P Kratz; Monique L den Boer; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

9.  Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.

Authors:  Brian V Balgobind; Pieter Van Vlierberghe; Ans M W van den Ouweland; H Berna Beverloo; Joan N R Terlouw-Kromosoeto; Elisabeth R van Wering; Dirk Reinhardt; Martin Horstmann; Gertjan J L Kaspers; Rob Pieters; C Michel Zwaan; Marry M Van den Heuvel-Eibrink; Jules P P Meijerink
Journal:  Blood       Date:  2008-01-02       Impact factor: 22.113

10.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Authors:  Nikesh Kotecha; Nikki J Flores; Jonathan M Irish; Erin F Simonds; Debbie S Sakai; Sophie Archambeault; Ernesto Diaz-Flores; Marc Coram; Kevin M Shannon; Garry P Nolan; Mignon L Loh
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743
View more
  15 in total

1.  Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.

Authors:  Friso G J Calkoen; Carly Vervat; Else Eising; Lisanne S Vijfhuizen; Peter-Bram A C 't Hoen; Marry M van den Heuvel-Eibrink; R Maarten Egeler; Maarten J D van Tol; Lynne M Ball
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Cleaning up the environment in juvenile myelomonocytic leukemia.

Authors:  Lisa Deng; Rebecca J Chan
Journal:  Transl Cancer Res       Date:  2017-02       Impact factor: 1.241

3.  Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Authors:  Charlotte M Niemeyer; Mignon L Loh; Annamaria Cseh; Todd Cooper; Christopher C Dvorak; Rebecca Chan; Blanca Xicoy; Ulrich Germing; Seiji Kojima; Atsushi Manabe; Michael Dworzak; Barbara De Moerloose; Jan Starý; Owen P Smith; Riccardo Masetti; Albert Catala; Eva Bergstraesser; Marek Ussowicz; Oskana Fabri; André Baruchel; Hélène Cavé; Michel Zwaan; Franco Locatelli; Henrik Hasle; Marry M van den Heuvel-Eibrink; Christian Flotho; Ayami Yoshimi
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

Review 4.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

Review 5.  Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Authors:  Nao Yoshida; Sayoko Doisaki; Seiji Kojima
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

6.  Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.

Authors:  Baskar Ramdas; Lisa Deng Yuen; Lakshmi Reddy Palam; Roshini Patel; Santhosh Kumar Pasupuleti; Victoria Jideonwo; Ji Zhang; Callista Maguire; Eric Wong; Rahul Kanumuri; Chujing Zhang; George Sandusky; Rebecca J Chan; Chi Zhang; Elliot Stieglitz; Laura Haneline; Reuben Kapur
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

7.  Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study.

Authors:  Franco Locatelli; Alessandro Crotta; Annalisa Ruggeri; Mary Eapen; John E Wagner; Margaret L Macmillan; Marco Zecca; Joanne Kurtzberg; Carmem Bonfim; Ajay Vora; Cristina Díaz de Heredia; Lochie Teague; Jerry Stein; Tracey A O'Brien; Henrique Bittencourt; Adrienne Madureira; Brigitte Strahm; Christina Peters; Charlotte Niemeyer; Eliane Gluckman; Vanderson Rocha
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

8.  Array-CGH as an adjuvant tool in cytogenetic diagnosis of pediatric MDS and JMML.

Authors:  Amanda Gonçalves Silva; Mariana Maschietto; Daniel Onofre Vidal; Leandro Mota Peliçario; Elvira Deolinda Rodrigues Pereira Velloso; Luiz Fernando Lopes; Ana Cristina Krepischi; Carla Rosenberg
Journal:  Med Oncol       Date:  2013-10-02       Impact factor: 3.064

9.  Molecular targets for the treatment of juvenile myelomonocytic leukemia.

Authors:  Xiaoling Liu; Himalee Sabnis; Kevin D Bunting; Cheng-Kui Qu
Journal:  Adv Hematol       Date:  2011-11-13

10.  Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.

Authors:  Peng Zhang; Fuhong He; Jie Bai; Shohei Yamamoto; Shi Chen; Lin Zhang; Mengyao Sheng; Lei Zhang; Ying Guo; Na Man; Hui Yang; Suyun Wang; Tao Cheng; Stephen D Nimer; Yuan Zhou; Mingjiang Xu; Qian-Fei Wang; Feng-Chun Yang
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.